# PT-141 FAQ: Common Questions Answered | PT-141 > PT-141 FAQ: what it is, how it works, what receptors it targets, the approved dose, half-life, and side effects — short, cited answers from the research. Short, cited answers to the questions people actually ask about PT-141 (bremelanotide). ## What is PT-141? PT-141, a synthetic alpha-MSH analogue, is an agonist at melanocortin receptors (MC3R/MC4R) found mostly in the central nervous system [1]. In animal studies it produced erections and activated hypothalamic neurons, and in men with erectile dysfunction it produced dose-dependent erectile activity — all consistent with a central, brain-based mechanism [1]. ## What is PT-141 peptide? PT-141 peptide is a cyclic ring of seven amino acids (a heptapeptide) modeled on alpha-MSH, a natural melanocortin signaling molecule [1]. Its ring shape makes it stable enough to act as a drug. It switches on brain melanocortin receptors tied to sexual desire rather than working on blood vessels [5]. ## What does the PT-141 peptide do? It activates central melanocortin receptors (mainly MC4R) in the hypothalamus, engaging brain circuits for sexual desire and arousal [1]. In approved use it modestly raised sexual desire and lowered desire-related distress in premenopausal women with HSDD over 24 weeks [3]. ## What is PT-141 used for? Its one FDA-approved use is hypoactive sexual desire disorder (distressingly low desire) in premenopausal women, as a 1.75 mg as-needed injection [7]. Every other use — in men, after menopause, or for performance — is off-label or investigational and not approved [7]. ## Is PT-141 the same as bremelanotide? Yes. Bremelanotide is the international nonproprietary name (the official generic name) for the peptide commonly called PT-141 [13]. The approved injection studied in the RECONNECT trials is bremelanotide [3]. Material sold as a "PT-141 research chemical" sits outside that approval, with no oversight of its identity or purity [7]. ## What is bremelanotide? Bremelanotide is a melanocortin MC3R/MC4R receptor agonist — a synthetic alpha-MSH analogue — approved in 2019 for HSDD in premenopausal women [7]. It works centrally in the brain on the circuitry of sexual desire, not on blood flow, which distinguishes it from erection pills [1]. ## What are the benefits of PT-141? In the approved population, the documented benefit is a modest but statistically significant rise in sexual desire (FSFI-desire +0.35) and a drop in desire-related distress over 24 weeks [3]. A 52-week extension showed the desire benefit was sustained [4]. Effects outside premenopausal women are not approved or proven. ## How does PT-141 work? PT-141 turns on melanocortin MC4R (and MC3R) receptors in the hypothalamus and limbic system, engaging dopaminergic circuits that govern sexual desire [1]. A human fMRI study confirmed this central mechanism — MC4R activation increased desire and changed how the brain processed erotic cues [5]. ## What receptors does PT-141 act on? Mainly the melanocortin 4 receptor (MC4R), with the melanocortin 3 receptor (MC3R) as a secondary target [1]. Both are central-nervous-system receptors. A separate skin receptor, MC1R, is responsible for the hyperpigmentation seen with frequent dosing [7]. ## Does PT-141 work through the brain or through blood flow? Through the brain. PT-141 acts centrally on the neural circuitry of sexual motivation, not peripherally on vascular smooth muscle [1]. A controlled fMRI study in women showed it altered central brain processing of erotic stimuli — direct evidence of a brain-based, not blood-flow-based, mechanism [5]. ## What is a melanocortin receptor agonist? A molecule that binds and switches on melanocortin receptors — a family of five (MC1R-MC5R) that respond to signals like alpha-MSH [1]. PT-141 is one such agonist, targeting the central MC3R and MC4R subtypes tied to sexual desire [1]. ## Does PT-141 increase testosterone? No. PT-141 does not act through the hypothalamic-pituitary-gonadal (HPG) axis and does not directly raise testosterone [9]. It works on melanocortin desire circuits, a separate system. The idea that it boosts testosterone is a common misconception, not a research finding [9]. ## How is PT-141 different from PDE-5 inhibitors? PDE-5 inhibitors act peripherally on blood vessels to improve erectile blood flow and do nothing for desire [9]. PT-141 acts centrally in the brain on the circuitry of sexual desire and arousal [1]. They target different links in the chain and are not interchangeable. ## What is the PT-141 dosage? The approved bremelanotide dosage is 1.75 mg subcutaneously, as needed, with a maximum of one dose per 24 hours and no more than 8 doses per month [7]. The terminal half-life is about 2.7 hours [7]. This is the documented label figure, not a recommendation for any individual. ## How much PT-141 should I take? This site recommends no dose to anyone. The only documented human regimen is the FDA-approved 1.75 mg subcutaneous as-needed dose for premenopausal women with HSDD [7]. Material sold as a research chemical has no verified concentration or purity, so no reliable dose can even be defined for it [7]. ## How much PT-141 to inject? The approved label specifies a single 1.75 mg subcutaneous injection, no more than once in 24 hours and no more than 8 times a month, for the approved indication [7]. That is the documented figure; this is editorial reporting of the label, not dosing instruction for any reader. ## What is the PT-141 dosage for women? For premenopausal women with HSDD, the approved dosage is 1.75 mg subcutaneous as-needed [7]. The supporting preclinical female work — a selective increase in solicitational behavior — was done in rats at research dose ranges, not human doses [2]. No dose is recommended here. ## How do you reconstitute PT-141? The approved bremelanotide product is supplied as a ready-to-use 1.75 mg subcutaneous injection, so the label does not describe reconstitution [7]. Powdered "research chemical" PT-141 is unregulated, with no verified identity or concentration, and this site provides no reconstitution or preparation instructions [7]. ## How do you take PT-141? The approved route is a subcutaneous (under-the-skin) injection, used as needed at least 45 minutes before anticipated activity, no more than once per 24 hours [7]. Intranasal and intravenous routes appeared in early development; intranasal was dropped for pharmacokinetic variability [7]. ## How often can you take PT-141? The label sets a maximum of one dose per 24 hours and no more than 8 doses per month [7]. In a 52-week open-label extension under this as-needed pattern, no new safety signals emerged, though nausea (40.4%) remained the leading tolerability issue [4]. ## What is the approved bremelanotide dose? 1.75 mg subcutaneous, as needed, for HSDD in premenopausal women [7]. This dose met both coprimary endpoints in the two Phase 3 RECONNECT trials (n=1,267), significantly improving sexual desire and reducing desire-related distress versus placebo over 24 weeks [3]. ## How long does PT-141 last? Its terminal half-life is about 2.7 hours (range 1.9-4.0), so it clears the blood within hours [7]. The felt effect can outlast the drug: a controlled fMRI study found increased sexual desire measurable for up to 24 hours after MC4R activation [5]. --- A cool cathode-blue reading desk for the PT-141 (bremelanotide) record — the one approved use, the modest measured benefit, and the nausea-led tolerability cost surfaced first and traced line by line to source, with the unverified field reports held off the lit panel and labeled plainly; a quiet instrument of the evidence, not a clinic, and nothing here dosed, sourced, or sold.